BioXcel Therapeutics (BTAI) Competitors $2.61 +0.07 (+2.76%) Closing price 04:00 PM EasternExtended Trading$2.62 +0.02 (+0.57%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BTAI vs. CCCC, PYXS, CTOR, THTX, ACOG, NVCT, NKTX, MOLN, GLSI, and BTMDShould you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include C4 Therapeutics (CCCC), Pyxis Oncology (PYXS), Citius Oncology (CTOR), Theratechnologies (THTX), Alpha Cognition (ACOG), Nuvectis Pharma (NVCT), Nkarta (NKTX), Molecular Partners (MOLN), Greenwich LifeSciences (GLSI), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry. BioXcel Therapeutics vs. Its Competitors C4 Therapeutics Pyxis Oncology Citius Oncology Theratechnologies Alpha Cognition Nuvectis Pharma Nkarta Molecular Partners Greenwich LifeSciences biote BioXcel Therapeutics (NASDAQ:BTAI) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment. Which has more risk and volatility, BTAI or CCCC? BioXcel Therapeutics has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 2.94, indicating that its share price is 194% more volatile than the S&P 500. Do institutionals and insiders hold more shares of BTAI or CCCC? 30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 21.2% of BioXcel Therapeutics shares are held by insiders. Comparatively, 8.7% of C4 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, BTAI or CCCC? BioXcel Therapeutics has higher earnings, but lower revenue than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioXcel Therapeutics$2.27M18.41-$59.60M-$12.64-0.21C4 Therapeutics$35.58M4.22-$105.32M-$1.58-1.34 Does the media refer more to BTAI or CCCC? In the previous week, BioXcel Therapeutics had 1 more articles in the media than C4 Therapeutics. MarketBeat recorded 4 mentions for BioXcel Therapeutics and 3 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.83 beat BioXcel Therapeutics' score of 0.48 indicating that C4 Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioXcel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral C4 Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer BTAI or CCCC? BioXcel Therapeutics currently has a consensus target price of $39.75, suggesting a potential upside of 1,422.99%. C4 Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 302.84%. Given BioXcel Therapeutics' higher probable upside, research analysts clearly believe BioXcel Therapeutics is more favorable than C4 Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 2 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.43C4 Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Is BTAI or CCCC more profitable? C4 Therapeutics has a net margin of -325.88% compared to BioXcel Therapeutics' net margin of -5,869.82%. BioXcel Therapeutics' return on equity of 0.00% beat C4 Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics-5,869.82% N/A -134.45% C4 Therapeutics -325.88%-53.91%-33.26% SummaryBioXcel Therapeutics and C4 Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BTAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTAI vs. The Competition Export to ExcelMetricBioXcel TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.66M$3.36B$6.05B$10.30BDividend YieldN/A2.31%5.73%4.82%P/E Ratio-0.2122.0885.3127.10Price / Sales18.41478.69601.46133.29Price / CashN/A44.9825.7730.18Price / Book-0.0910.3812.676.69Net Income-$59.60M-$52.47M$3.32B$276.55M7 Day Performance2.35%0.59%-0.44%-1.14%1 Month Performance-16.08%13.95%8.72%6.50%1 Year Performance-69.02%29.25%75.69%33.95% BioXcel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTAIBioXcel Therapeutics4.2853 of 5 stars$2.61+2.8%$39.75+1,423.0%-69.8%$40.66M$2.27M-0.2190Positive NewsCCCCC4 Therapeutics3.6242 of 5 stars$2.28+0.4%$8.50+272.8%-58.8%$161.56M$35.58M-1.44150PYXSPyxis Oncology1.9472 of 5 stars$2.47-3.9%$7.75+213.8%+14.4%$159.39M$16.15M-1.5460Gap DownCTORCitius Oncology3.0032 of 5 stars$1.87-1.1%$6.00+220.9%+69.3%$157.84MN/A0.00N/AGap UpTHTXTheratechnologiesN/A$3.42+0.9%N/A+172.4%$157.21M$84.38M-17.99140Upcoming EarningsHigh Trading VolumeACOGAlpha Cognition3.1089 of 5 stars$7.40-1.1%$20.00+170.3%N/A$156.35MN/A-4.63N/ANVCTNuvectis Pharma3.08 of 5 stars$6.05+0.7%$15.33+153.4%-6.9%$152.87MN/A-5.178NKTXNkarta2.3728 of 5 stars$2.15+0.9%$13.60+532.6%-44.5%$151.28MN/A-1.45140News CoverageHigh Trading VolumeMOLNMolecular Partners1.6558 of 5 stars$3.72+0.3%$8.00+115.0%-19.8%$149.79M$5.65M-1.79180GLSIGreenwich LifeSciences1.1084 of 5 stars$11.28+3.4%$42.00+272.3%-22.4%$148.71MN/A-8.293Gap UpBTMDbiote2.3224 of 5 stars$2.91-2.3%$6.00+106.2%-47.3%$147.33M$197.19M3.23194 Related Companies and Tools Related Companies C4 Therapeutics Alternatives Pyxis Oncology Alternatives Citius Oncology Alternatives Theratechnologies Alternatives Alpha Cognition Alternatives Nuvectis Pharma Alternatives Nkarta Alternatives Molecular Partners Alternatives Greenwich LifeSciences Alternatives biote Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTAI) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
